A Phase 2 interventional study of MK-8527 and Placebo to MK-8527 in HIV and HIV Pre-exposure Prophylaxis, sponsored by Merck Sharp & Dohme LLC. Completed at 18 sites in 3 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This double-blind, placebo-controlled study was designed to assess the safety, tolerability, and pharmacokinetics of oral MK-8527 taken once monthly (QM) in participants at low risk for human immunodeficiency virus Type 1 (HIV-1) infection.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive oral MK-8527 low dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
Drug: MK-8527
Participants receive oral MK-8527 medium dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
Drug: MK-8527
Participants receive oral MK-8527 high dose QM for 6 months, followed by an 8-week blinded safety follow-up period.
Drug: MK-8527
Participants receive oral placebo matched to MK-8527 QM for 6 months, followed by an 8-week blinded safety follow-up period.
Drug: Placebo to MK-8527
MK-8527 capsule
Placebo capsule matched to MK-8527
Number of Participants With ≥1 Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to ~28 weeks
Number of Participants Discontinuing Study Therapy Due to Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to ~20 weeks
Area Under the Plasma Concentration-Time Curve From Dosing to Last Measurable Concentration (AUC0-last) of MK-8527
The plasma AUC0-last of MK-8527 is reported.
Time frame: Day 1: predose and 0.5, 4, and 24 hours postdose. Week 20: 0.5, 4, and 24 hours postdose
Maximum Plasma Concentration (Cmax) of MK-8527
The plasma Cmax of MK-8527 is reported.
Time frame: Day 1: predose and 0.5, 4, and 24 hours postdose. Week 20: 0.5, 4, and 24 hours postdose
Adult participants who were at low risk of human immunodeficiency virus Type 1 (HIV-1) infection were recruited.
| Milestone | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 |
|---|---|---|---|---|
| Started | 101 | 102 | 100 | 49 |
| Completed | 92 | 97 | 98 | 46 |
| Not completed | 9 | 5 | 2 | 3 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 3 | 0 | 0 |
| Withdrew: Randomized by mistake (no study treatment given) | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 | 0 | 2 |
| Withdrew: Miscellaneous | 2 | 0 | 0 | 1 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 |
|---|---|---|---|---|
| Number of Participants With ≥1 Adverse Event (AE) | 62 | 69 | 66 | 31 |
The plasma AUC0-last of MK-8527 is reported.
| hr*µmol/L | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 |
|---|---|---|---|---|
| Day 1 | 0.132 ± 84.8 | 0.397 ± 36.1 | 0.861 ± 34.1 | — |
| Week 20 | 0.129 ± 81.5 | 0.404 ± 37.3 | 0.836 ± 55.0 | — |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 |
|---|---|---|---|---|
| Number of Participants Discontinuing Study Therapy Due to Adverse Event (AE) | 0 | 2 | 1 | 2 |
The plasma Cmax of MK-8527 is reported.
| µmol/L | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 |
|---|---|---|---|---|
| Day 1 | 0.0289 ± 69.0 | 0.0490 ± 75.6 | 0.113 ± 64.5 | — |
| Week 20 | 0.0320 ± 67.5 | 0.0538 ± 73.5 | 0.108 ± 72.5 | — |
Collected over Up to ~28 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MK-8527 3 mg QM | 0/101 (0%) | 2/101 (2%) | 38/101 (37.6%) |
| MK-8527 6 mg QM | 0/101 (0%) | 0/101 (0%) | 43/101 (42.6%) |
| MK-8527 12 mg QM | 1/99 (1%) | 1/99 (1%) | 32/99 (32.3%) |
| Placebo to MK-8527 | 0/49 (0%) | 1/49 (2%) | 21/49 (42.9%) |
| Event | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 |
|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/101 | 0/101 | 0/99 | 1/49 |
| Gun shot woundInjury, poisoning and procedural complications | 0/101 | 0/101 | 1/99 | 0/49 |
| Abdominal painGastrointestinal disorders | 1/101 | 0/101 | 0/99 | 0/49 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/101 | 0/101 | 0/99 | 0/49 |
| Event | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 16/101 | 10/101 | 10/99 | 6/49 |
| HeadacheNervous system disorders | 9/101 | 7/101 | 1/99 | 0/49 |
| NasopharyngitisInfections and infestations | 3/101 | 2/101 | 2/99 | 4/49 |
| NauseaGastrointestinal disorders | 4/101 | 8/101 | 3/99 | 1/49 |
| FatigueGeneral disorders | 5/101 | 8/101 | 7/99 | 3/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/101 | 7/101 | 1/99 | 0/49 |
| Blood creatine phosphokinase increasedInvestigations | 3/101 | 1/101 | 3/99 | 3/49 |
| Lymphocyte count decreasedInvestigations | 0/101 | 1/101 | 6/99 | 1/49 |
| COVID-19Infections and infestations | 2/101 | 4/101 | 5/99 | 2/49 |
| CD4 lymphocytes decreasedInvestigations | 4/101 | 3/101 | 5/99 | 1/49 |
| Age, Continuous(Years) | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 | Total |
|---|---|---|---|---|---|
| Mean | 30.4 ± 10.12 | 30.0 ± 9.80 | 29.6 ± 8.84 | 29.8 ± 8.90 | 30.0 ± 9.48 |
| Sex: Female, Male(Participants) | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 | Total |
|---|---|---|---|---|---|
| Female | 58 | 59 | 58 | 29 | 204 |
| Male | 43 | 42 | 41 | 20 | 146 |
| Ethnicity (NIH/OMB)(Participants) | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 18 | 13 | 14 | 11 | 56 |
| Not Hispanic or Latino | 83 | 86 | 84 | 38 | 291 |
| Unknown or Not Reported | 0 | 2 | 1 | 0 | 3 |
| Race (NIH/OMB)(Participants) | MK-8527 3 mg QM | MK-8527 6 mg QM | MK-8527 12 mg QM | Placebo to MK-8527 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 2 | 3 | 0 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 44 | 40 | 40 | 21 | 145 |
| White | 49 | 54 | 51 | 26 | 180 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 5 | 5 | 2 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Nov 2023 to primary completion in Dec 2024, 13 months.
Results were first posted in Jan 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alimatravir